Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adelaide A Hebert

Showing results (91-100 of 150) with videos related to

Pageof 15
Sort By:
Brachytherapy|August 14, 2012
A new paradigm for calculating skin doseKent A Gifford, Omar Pacha, Adelaide A Hebert, et al.
Paediatric Drugs|March 16, 2022
Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 YearsThomas A Luger, Adelaide A Hebert, Andrea L Zaenglein, et al.
Advances in Skin & Wound Care|June 16, 2017
Skin and Wound Care in Lymphedema Patients: A Taxonomy, Primer, and Literature ReviewCaroline E Fife, Wade Farrow, Adelaide A Hebert, et al.
Pediatric Dermatology|April 16, 2019
Sodium hypochlorite body wash in the management of Staphylococcus aureus-colonized moderate-to-severe atopic dermatitis in infants, children, and adolescentsSara Majewski, Tanya Bhattacharya, Manuela Asztalos, et al.
Journal of Drugs in Dermatology : JDD|March 4, 2026
Expert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand EczemaApril W Armstrong, Yvonne Nong, Christopher G Bunick, et al.
Pediatric Dermatology|May 20, 2016
Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure StudyLee T Zane, Leon Kircik, Robert Call, et al.
Journal of the American Academy of Dermatology|June 11, 2026
Reconstitution, Storage, and Infection Outcomes of Botulinum Toxin in Academic Dermatology: A National SurveyBianca Y Kang, Murad Alam, Adelaide A Hebert, et al.
JAMA Dermatology|May 26, 2018
Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical TrialMary Kay Koenig, Cynthia S Bell, Adelaide A Hebert, et al.
Journal of Drugs in Dermatology : JDD|September 5, 2025
The Atopic Dermatitis Continuum: An Updated Paradigm for a Common Disorder and a Novel Multipurpose Treatment OptionLawrence A Schachner, Adelaide A Hebert, Nanette Silverberg, et al.
American Journal of Clinical Dermatology|March 24, 2025
Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic DermatitisAmy S Paller, Adelaide A Hebert, Mercedes E Gonzalez, et al.
Pageof 15

Showing results (91-100 of 150) with videos related to

Sort By:
Pageof 15
Brachytherapy|August 14, 2012
A new paradigm for calculating skin doseKent A Gifford, Omar Pacha, Adelaide A Hebert, et al.
Paediatric Drugs|March 16, 2022
Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 YearsThomas A Luger, Adelaide A Hebert, Andrea L Zaenglein, et al.
Advances in Skin & Wound Care|June 16, 2017
Skin and Wound Care in Lymphedema Patients: A Taxonomy, Primer, and Literature ReviewCaroline E Fife, Wade Farrow, Adelaide A Hebert, et al.
Pediatric Dermatology|April 16, 2019
Sodium hypochlorite body wash in the management of Staphylococcus aureus-colonized moderate-to-severe atopic dermatitis in infants, children, and adolescentsSara Majewski, Tanya Bhattacharya, Manuela Asztalos, et al.
Journal of Drugs in Dermatology : JDD|March 4, 2026
Expert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand EczemaApril W Armstrong, Yvonne Nong, Christopher G Bunick, et al.
Pediatric Dermatology|May 20, 2016
Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure StudyLee T Zane, Leon Kircik, Robert Call, et al.
Journal of the American Academy of Dermatology|June 11, 2026
Reconstitution, Storage, and Infection Outcomes of Botulinum Toxin in Academic Dermatology: A National SurveyBianca Y Kang, Murad Alam, Adelaide A Hebert, et al.
JAMA Dermatology|May 26, 2018
Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical TrialMary Kay Koenig, Cynthia S Bell, Adelaide A Hebert, et al.
Journal of Drugs in Dermatology : JDD|September 5, 2025
The Atopic Dermatitis Continuum: An Updated Paradigm for a Common Disorder and a Novel Multipurpose Treatment OptionLawrence A Schachner, Adelaide A Hebert, Nanette Silverberg, et al.
American Journal of Clinical Dermatology|March 24, 2025
Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic DermatitisAmy S Paller, Adelaide A Hebert, Mercedes E Gonzalez, et al.
Pageof 15